PHR vs DOCS

For growth investors, Doximity, Inc.

(DOCS) is the stronger pick with 20. 0% revenue growth year-over-year, versus 17. 8% for Phreesia, Inc. (PHR). Doximity, Inc. (DOCS) offers the better valuation at 23. 1x trailing P/E (16. 6x forward), making it the more compelling value choice. Analysts rate Phreesia, Inc. (PHR) a "Buy" — based on 25 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Doximity, Inc.

is actually cheaper at 16. 6x.

Over the past 5 years, Doximity, Inc.

(DOCS) delivered a total return of -51. 5%, compared to -80. 2% for Phreesia, Inc. (PHR). Over 10 years, the gap is even starker: DOCS returned -51. 5% versus PHR's -62. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Phreesia, Inc.

(PHR) is the lower-risk stock at 0. 79β versus Doximity, Inc. 's 1. 03β — meaning DOCS is approximately 30% more volatile than PHR relative to the S&P 500. On balance sheet safety, Doximity, Inc. (DOCS) carries a lower debt/equity ratio of 1% versus 7% for Phreesia, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Doximity, Inc.

(DOCS) is pulling ahead at 20. 0% versus 17. 8% for Phreesia, Inc. (PHR). On earnings-per-share growth, the picture is similar: Phreesia, Inc. grew EPS 59. 4% year-over-year, compared to 54. 2% for Doximity, Inc.. Over a 3-year CAGR, PHR leads at 25. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Doximity, Inc.

(DOCS) is the more profitable company, earning 39. 1% net margin versus -13. 9% for Phreesia, Inc. — meaning it keeps 39. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DOCS leads at 39. 9% versus -13. 8% for PHR. At the gross margin level — before operating expenses — DOCS leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Doximity, Inc.

(DOCS) trades at 16. 6x forward P/E versus 29. 6x for Phreesia, Inc. — 13. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PHR: 181. 8% to $26. 86.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Phreesia, Inc.

(PHR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 79)). Both have compounded well over 10 years (PHR: -62. 0%, DOCS: -51. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.